Inicio>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Mal-amido-PEG10-C2-NHS ester

Mal-amido-PEG10-C2-NHS ester

Catalog No.GC38563

El éster de mal-amido-PEG10-C2-NHS es un conector ADC no escindible que contiene un grupo maleimida y un éster de NHS. El éster de NHS se puede utilizar para marcar las aminas primarias (-NH2) de proteínas, oligonucleótidos modificados con amina y otras moléculas que contienen amina.

Products are for research use only. Not for human use. We do not sell to patients.

Mal-amido-PEG10-C2-NHS ester Chemical Structure

Cas No.: 1137109-22-8

Tamaño Precio Disponibilidad Cantidad
50mg
214,00 $
Disponible
100mg
342,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Mal-amido-PEG10-C2-NHS ester is a nonclaevable ADC linker containing a maleimide group and an NHS ester. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules[1][2].

[1]. Hansen AM, et al. Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. Eur J Med Chem. 2019 Apr 15;168:134-145. [2]. Zhang ge, et al. Preparation and application of FAPalpha activated polypeptide magnetic nanosphere compound used for diagnosis of tumors. CN105524141A

Reseñas

Review for Mal-amido-PEG10-C2-NHS ester

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Mal-amido-PEG10-C2-NHS ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.